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LRRC4/NGL-2 (Leucine rich repeat containing 4/Netrin-G ligand-2), a relatively specific expressed gene in brain
tissue, is a member of the LRRC4/ NGL (netrin-G ligand) family and belongs to the superfamily of LRR proteins.
LRRC4/NGL-2 regulates neurite outgrowth and lamina-specific dendritic segmentation, suggesting that LRRC4/NGL-2 is
important for the development of the nervous system. In addition, LRRC4/NGL-2 has been identified as a tumor
suppressor gene. The overexpression of LRRC4/NGL-2 suppresses glioma cell growth, angiogenesis and invasion
through complicated signaling regulation networks. LRRC4/NGL-2 also has the ability to form multiphase loops
with miRNA, transcription factors and gene methylation modification; the loss of LRRC4/NGL-2 function may be
an important event in multiple biological processes in gliomas. In summary, LRRC4/NGL-2 is a critical gene in the
normal development and tumorigenesis of the nervous system.
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The leucine-rich repeat (LRR) superfamily is composed
of a notably heterogeneous group of proteins containing
leucine-rich domains (LRR domain) known to mediate
highly specific protein-protein interaction or cell adhe-
sion. Many of LRR-containing proteins are involved in
the differentiation and development of normal nervous
tissues [1-6].
The LRRC4 (GenBank accession No. AF196976) gene
was cloned and characterized from human chromosome
7q31-32 using a computer-assisted positional cloning
strategy combining 5'-RACE [7]. Lin et al. (2003) deter-
mined that there is a similarity of phenotype and se-
quence between LRRC4 and the netrin-G1 ligand [8].
Afterwards, Kim et al. demonstrated that LRRC4 directly
interacts with netrin-G2, indicating that it is a ligand for
netrin-G2; thus, LRRC4 is also named NGL-2 (netrin-G
ligand-2) [9].
A genomic database analysis has since identified that
LRRC4 is a member of the LRRC4 (NGL, netrin-G ligand)
family and belongs to the superfamily of LRR proteins.* Correspondence: wuminghua554@aliyun.com
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family; LRRC4C (NGL-1), LRRC4 (NGL-2) and LRRC4B
(NGL-3) [10]. LRRC4/NGL-2 displays down-regulation or
expression deletion in primary brain tumor biopsies and
has the potential to suppress brain tumor growth [7].
Structure and distribution of LRRC4/NGL-2
LRRC4/NGL-2 is a member of the LRR superfamily. It con-
tains two segments at its N-terminus and C-terminus for
sequences representing a putative signal peptide and a
transmembrane region, respectively. Following the signal
peptide, the core LRR region consists of nine LRRs accom-
panied by typical amino-flanking (AF) and carboxy-flanking
(CF) clusters [1]. The amino-terminal LRR-flanking domain
contains cysteines in a C–X3–C–X–C–X8–C pattern,
whereas the carboxy–terminal LRR-flanking domain con-
forms to a P–X2–C–X–C–X19–C–X2–C pattern. Cytosine
clusters are known to enhance the stability of the central
LRRs [11]. Adjacent to the CF region, one IgC2 domain
is identified [8]. The transmembrane domain is
followed by a cytoplasmic region, which ends with a
PDZ domain-binding motif [12]. LRRC4C/NGL-1,
LRRC4/NGL-2, and LRRC4B/NGL-3 share the same
domain structure (Figure 1). The LRRC4 family displays
a sequence identity of approximately 57-61% in theis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Domain structure of LRRC4/NGL-2. LRR NT/CT, N- or
C-terminal LRR; LRR, leucine-rich repeat; Ig, immunoglobulin; TM,
transmembrane; PDZ, PSD-95/Dlg/ZO-1.
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show essentially no sequence identity, except in the PDZ-
binding motif. Moreover, the extracellular region immedi-
ately preceding the transmembrane domain varies signifi-
cantly among LRRC4s, suggesting that each LRRC4 may
have a distinct function [10].
LRRC4/NGL-2 displayed a brain-specific expression
pattern both in humans and mice. LRRC4/NGL-2 was
detected in the human brain but not in other normal tis-
sues including the heart, lung, liver and so on [13,14].
The mRNAs for LRRC4C/NGL-1 and LRRC4B/NGL-3
are mainly expressed in the brain, with minor expression
in the liver and heart, respectively. The transcripts of the
LRRC4 family members are distributed in distinct re-
gions of embryonic and postnatal brains [9,8,13,15].
LRRC4/NGL-2 expression in both the human and mice
brain was limited to the following areas: cerebellum, cere-
bral cortex, occipital pole, frontal lobe, temporal lobe and
putamen [13]. The LRRC4C/NGL-1 and LRRC4B/NGL-3
proteins have been indicated to be mainly expressed in the
brain but not in other tissues [9]. The absence of
LRRC4C/NGL-1 and LRRC4B/NGL-3 protein expression
in the liver and heart, respectively, is dissimilar to their
mRNA expression patterns. The LRRC4C/NGL-1 protein
is detected in the hippocampus, neocortex, and piriform
cortex (Table 1). Within neurons, LRRC4/NGL-2 and
LRRC4C/NGL-1 are selectively localized to distinct den-
dritic segments [15]. LRRC4/NGL family members are
mainly localized to the postsynaptic side of excitatory
synapses, and NGL-1 interacts with netrin-G1, NGL-2
with netrin-G2, and NGL-3 with LAR, which playTable 1 The expression distribution of the LRRC4 family
in brain tissues
LRRC4 family Protein distribution
LRRC4/NGL-2 cerebellum, cerebral cortex, occipital pole,
frontal lobe, temporal lobe, and putamen
LRRC4C/NGL-1 hippocampus, neocortex, and piriform cortex
LRRC4B/NGL-3 similar brain-specificimportant roles in the development of axons, dendrites
and synapses [10].
Role of LRRC4/NGL-2 in maintaining normal
function in the central nervous system
A number of leucine-rich repeat proteins with LRRs and
Ig regions, which seem to serve similar functions, have
been found to be expressed predominantly in cells of
nervous tissues [8,16,17], and are involved in the differ-
entiation and development of normal nervous tissues
[1,2]. LRRC4C/NGL-1, LRRC4/NGL-2 and LRRC4B/
NGL-3 share the same domain structure. The structure
character of LRRC4s implies that these genes might be
involved in the development and differentiation of the
nervous system. LRRC4C/NGL-1 was first identified as a
ligand for netrin-G1 [8]. LRRC4C/ NGL-1 has been
found to interact with netrin-G1 but not with netrin-G2.
In addition, LRRC4/NGL-2 interacts with netrin-G2
but not with netrin-G1 [9]. LRRC4B/NGL-3 does not
interact with either netrin-G1 or netrin-G2 but was
determined to interact with the receptor tyrosine phos-
phatase LAR [10,18]. The interaction between netrin-
G1 and LRRC4C/NGL-1 has been implicated in the
regulation of axonal outgrowth and migration [8]. The
LRRC4C/NGL1-netrinG1 and LRRC4/NGL2-netrinG2
interactions have been implicated in the lamina-specific
segmentation of dendrites [15]. In the early development
of the brain, the expression of mLRRC4/NGL-2 increased
with age, suggesting a possible role of LRRC4/NGL-2 in
brain development [13]. LRRC4/NGL-2 regulates the
formation of excitatory synapses through the recruit-
ment of pre- and postsynaptic proteins [19], partici-
pates in the differentiation of neuron and glia cells, and
promotes neurite outgrowth [20]. In addition,LRRC4/
NGL-2 formed a complex with the NMDA receptor
subunits involved in the regulation of NMDA(N-me-
thyl-D-aspartate) receptor-mediated excitatory synaptic
transmission [9]. LRRC4/NGL-2 is localized to the den-
dritic segment in the stratum radiatum of CA1(Cornu
Ammonis 1 area) and functions as a key regulator of
input-specific synapse development, which is critical
for the functional integration of distinct inputs [21].
LRRC4/NGL-2 was found to localize selectively to the tips
of HC(horizontal cell) axons, which form reciprocal con-
nections with rods; moreover, LRRC4/NGL-2 works as a
central component of pathway-specific development in
the outer retina [22]. LRRC4B/NGL-3–LAR interaction
is capable of mediating cell aggregation [23]. LRRC4B/
NGL-3 might be involved in the maturation of excita-
tory synapses. A suggested function of the LRRC4B/
NGL-3–LAR interaction is synapse formation [23]. The
results from studies on the LRRC4 family suggest that
LRRC4s play important roles in maintaining normal
function in the central nervous system. In addition to
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teins play a role in glial cells [10].
Aberrant expression of LRRC4/NGL-2 in tumors of
the central nervous system
LRRC4/NGL-2 was found to be predominantly expressed
in the normal brain tissues, though it was deleted or
down-regulated in primary brain tumor biopsies (up to
87.5% in gliomas, 80.9% in meningiomas and 85.2% in pi-
tuitary and other brain tumors) [7]. LRRC4/NGL-2 was
highly specific in brain tissue and grade I gliomas (WHO),
but it was reduced or absent in grade II-III gliomas and
absent in glioblastoma (WHO, grade IV) [24]. Thus, the
loss of LRRC4/NGL-2 function may directly contribute to
the increasing tumor grade and is a late event in the
pathogenesis of gliomas. Furthermore, LRRC4/NGL-2 is
downregulated expression in pituitary adenoma, polymor-
phisms or haplotypes in the LRRC4/NGL-2 and may have
important research significance by predicting the risk of
pituitary adenoma [25].
Role of LRRC4/NGL-2 as a tumor suppressor gene
in glioma tumorigenesis
LRRC4/NGL-2 significantly inhibited glioma cell prolif-
eration and greatly reduced its capacity to form colonies
[24]. Furthermore, it reduced the growth and malignant
grade of xenografts arising from glioma cells. The ultra-
structure of glioma cell Tet-on-LRRC4/NGL-2 under-
went a significant change, the nucleo-cytoplasmic ratio
lessened, the nuclear shape became regular, heterochro-
matin in nuclei decreased while euchromatin increased,
the volume of nucleoli lessened, rough ER increased sig-
nificantly, the Golgi apparatus was well-developed and
Golgi vesicles increased and were regularly arranged,
most mitochondria were oval and their crista grew in
number and were regularly arranged, and finally polyri-
bosomes reduced while free ribosomes increased [26]. In
addition, it has the ability to inhibit the invasion and
angiogenesis of glioma cells.
LRRC4/NGL-2 suppressed glioma cell proliferation by
delaying the cell cycle in late G1 and did not induce
apoptosis of tumor cells [26]. Furthermore, LRRC4/
NGL-2 inhibited the glioma tumor cell invasion through
regulating the expression of the invasion-related mole-
cules including CD44, MMP16, TB10 and annexin A2
[27]. In addition, LRRC4/NGL-2 might be a negative
regulator of the RPTP-zeta receptor, contributing to the
suppression of the invasion ability of glioma cells [28].
The reintroduction of LRRC4/NGL-2 might inhibit the
expression of CXCR4 and SDF-1α/CXCR4 axis-mediated
cell invasion in vitro [29]. Moreover, LRRC4/NGL-2 in-
hibits glioblastoma cell proliferation, migration and angio-
genesis by downregulating pleiotropic cytokine expression
and response [30]. Together, these findings demonstratedthat LRRC4/NGL-2 can be identified as a tumor suppres-
sor gene in the tumorigenesis of glioma. The inhibitory ef-
fect of LRRC4/NGL-2 on cell proliferation and invasion is
dependent on its LRR cassette domain but not on IgC2 or
Tm domain. In the LRR cassette domain, the third LRR
motif of the core LRR is found to be indispensable for the
function of LRRC4/NGL-2, and it plays a crucial role as a
“proliferation-inhibition switch”. The seventh LRR motif
plays a crucial role as an “invasion-inhibition switch” [24].
Signaling transduction network of LRRC4/NGL-2
in glioma
To further analyze the mechanisms of LRRC4/NGL-2
on the suppression of tumorigenesis and progression in
gliomas, Zhang et al. investigated alterations in gene ex-
pression related to the neurobiology of the Atlas array
and found that 1) The overexpression of LRRC4/NGL-2
can elevate the expression levels of certain cell cycle pro-
gression regulators, such as RAP1GAP, ephrin-B3, som-
atostatin receptors, PTPN and NT-3, and regulate
suppressing cell cycle progression by impacting on Raf/
Rap/Ras pathways; 2) the overexpression of LRRC4/
NGL-2 can down-regulate the expression of genes in-
volved in tumor invasion and metastasis, including
CD44, MMP16, Thymosin beta-10 and AnnexinA2; and
3) LRRC4/NGL-2 may act as a receptor for adhesion
molecule Netrin-G2 by participating in the inhibition of
tumorigenesis and suppression of glioma tumorigenesis
by preventing the synthesis and release of toxic neuro-
transmitters [27]. LRRC4/NGL-2 can delay the cell cycle
in late G1 by increasing the expression of cell cycle in-
hibitory molecules (p21, p27) and reducing the expres-
sion of cell cycle regulatory proteins (CyclinD1, CDK2,
CyclinE, CDK4) via the down-regulation of growth fac-
tors (IGF, bFGF, EGF, PDGF, VEGF SDF-1α) or recep-
tors, the inhibition of K-Ras/c-Raf/ERK/MAPK, PI-3 K/
AKT/NF- κB, p70S6/PKC and STAT3, and the upregula-
tion of the JNK2/c-Jun/mp53 (mutant p53) signaling
pathway [24,27]. Moreover, the PMA-stimulated activa-
tion of PKC activates PI3K/Akt, but not pERK, in the
presence of LRRC4/NGL-2, which is consistent with the
fact that PKC is located downstream of ERK but up-
stream of PI3K/Akt [24]. The reintroduction of LRRC4/
NGL-2 in U251 cells inhibits the expression of CXCR4
(CXC chemokine receptor 4) and SDF-1 (stromal cell-
derived factor-1) alpha/CXCR4 axis-mediated downstream
intracellular pathways such as ERK1/2 and Akt leading to
proliferate, chemotactic and invasive effects (Figure 2) [29].
Epigenetic changes of LRRC4/NGL-2 in glioma
LRRC4/NGL-2 was a candidate tumor suppressor gene
that may be involved in the pathogenesis of malignant
glioma. However, no genetic alterations of the LRRC4/
NGL-2 coding region were found in glioma [24]. The
Figure 2 Schematic diagram showing the signaling regulation network of LRRC4/NGL-2 in glioma. LRRC4/NGL-2 can delay the cell cycle
in late G1 by increasing the expression of cell cycle inhibitory molecules (p21, p27) and reducing the expression of cell cycle regulatory proteins
(CyclinD1, CDK2, CyclinE, CDK4) via the inhibition of K-Ras/c-Raf/ERK/MAPK, PI-3K/AKT/NF- κB, p70S6/PKC and STAT3, and the upregulation of the
JNK2/c-Jun/mp53 signaling pathway. LRRC4 /NGL-2 inhibits the expression of CXCR4 and SDF-1 alpha/CXCR4 axis-mediated downstream intracellular
pathways leading to proliferate, chemotactic and invasive effects.
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found to be a frequent and glioma-specific event. Fur-
thermore, the methylation of LRRC4/NGL-2 was de-
tected in both the early and late stages of glioma,
indicating that the inactivation of the LRRC4/NGL-2
gene might be essential in the early development of gli-
oma and persist through the course of development
[31]. Both DNA methylation and histone modification
are not isolated epigenetic events; there are cross-talks
between them. Trimethyl-H3 (Lys9) is correlated with
LRRC4/NGL-2 promoter methylation, which suppresses
LRRC4/NGL-2 expression and H3 acetylation, while
trimethyl-H3 (lys4) is correlated with LRRC4/NGL-2
promoter demethylation, which activates LRRC4/NGL-2
expression [32].
The other dysregulation mechanisms of LRRC4/NGL-2
in glioma result from the miRNA-dependent regulatory
network.
LRRC4/NGL-2 as the core of miRNA-dependent
multiphase loops in glioma
MicroRNAs (miRNAs) are approximately 22 nt non-
coding RNAs that interfere with the translation of coding
mRNAs in a sequence-specific manner [33]. MiRNAs
function as tumor suppressors or oncogenes to inducecellular transformation and tumorigenesis [34-36].
MiRNA-mediated gene regulation is now considered to
be important in numerous biological processes and is
also recognized as being crucial for regulating gene
expression in tumors [37,38]. Several key studies on
miRNA expression patterns in gliomas have been com-
pleted to date. The abnormal expression of some miR-
NAs (miR-12b, miR-21, miR-221, miR-128, miR-181a,
miR-181b and miR-181c et al.) were found in gliomas
and might be involved in tumorigenesis and develop-
ment [25,39-41]. A greater number of studies have been
completed via the siRNA profiling of glioma; correla-
tions between siRNA templates, their target genes, and
candidate miRNA may help experimentally identify can-
didate miRNA targets in glioma [42]. LRRC4/NGL-2 is a
target gene of some miRNAs (such as miR-182 and miR-
381); meanwhile, it is capable of regulating miRNAs as a
tumor suppressor and forms multiphase loops with miR-
NAs, transcription factors and gene methylation modifi-
cation in glioma [43-46].
The LRRC4/NGL-2-AP-2-miR-182- LRRC4/NGL-2 Loop
There is a set of cis-acting elements in the promoters of
many miRNAs, which are regulated by a series of up-
stream transcription factors (TFs) [47]. Similar to the
Figure 3 Schematic diagram showing the multi-regulation
loops of LRRC4/NGL-2, miRNAs, TFs and target genes in glioma.
LRRC4/NGL-2-AP-2-miR-182- LRRC4/NGL-2 loop: LRRC4/NGL-2 is a
target of miR182; meanwhile, the overexpression of LRRC4/NGL-2
downregulated the expression of miR182. The transcription of miR-182
was induced by AP-2; meanwhile, miR-182 can inhibit the expression
of LRRC4/NGL-2, and LRRC4/NGL-2 can inhibit the expression of AP-2
though negatively regulating the ERK/MAPK and PI-3K/AKT signaling
pathways. The LRRC4/NGL-2-AP-2-miR-182- LRRC4/NGL-2 loop was
formed among LRRC4/NGL-2, miR-182 and AP-2. LRRC4/NGL-2-miR-
185-DNMT1-LRRC4/NGL-2 loop: The overexpression of LRRC4/NGL-2
could increase the expression of miR-185, while miR-185 could regulate
global methylation by targeting DNMT1 and increasing the expression
of LRRC4/NGL-2. LRRC4/NGL-2-SP1-DNMT1-LRRC4/NGL-2 loop: DNMT1
was positively regulated by SP1, and it could increase the expression of
LRRC4/NGL-2, while LRRC4/NGL-2 could also inhibit SP1 by negatively
regulating the ERK/MAPK and PI-3K/AKT signal pathway.
Li et al. Molecular Cancer 2014, 13:266 Page 5 of 7
http://www.molecular-cancer.com/content/13/1/266transcription of the protein-coding gene, TFs regulate
miRNA expression at the transcriptional level. Further,
miRNA might influence the expression of its target genes
and constitute a TF-miRNA-gene regulatory network
[48,49]. Genes not only modulate the expression of
miRNA target genes by influencing TF-mediated miR-
NAs expression but also regulate TFs through miRNAs
[50,51]. In the regulatory processes where target genes
are modulated by both miRNAs and transcription fac-
tors, TFs regulate miRNAs, and miRNAs suppress TFs.
In this way, multiphase loops might be constituted at
last [52-54].
LRRC4/NGL-2 is a target gene of miR-381 and
miR182; meanwhile, the overexpression of LRRC4/NGL-
2 downregulated the expression of miR-381 and miR182
in glioma cells [43-45]. The interactions between miR-
381/miR182 and LRRC4/NGL-2 were identified to be in-
volved in the pathological progression of astrocytoma
[43]. BRD7, a transcriptional cofactor for p53, is highly
expressed and negatively correlated with LRRC4/NGL-2
expression in gliomas. Disturbing miR-182 and miR-381
inhibits the expression of BRD7, arrests glioma cells in
the G0/G1 phase of the cell cycle, inhibits glioma cell
growth and induces differentiation of glioma cells to
astrocyte-like cell by upregulating LRRC4/NGL-2 and
suppressing the LRRC4/NGL-2-mediated binding of AP-
2/SP1/E2F6/c- Myc to BRD7 in ERK/MAPK and PI-3
K/AKT signal pathways [43,45].
The transcription of miR-182 was induced by tran-
scription factor AP-2; meanwhile,miR-182 can inhibit
the expression of LRRC4/NGL-2, and LRRC4/NGL-2
might inhibit the expression of AP-2 though negatively
regulating the ERK/MAPK and PI-3 K/AKT signaling
pathways. It was demonstrated that the LRRC4-AP-2-
miR-182-LRRC4 loop formed among LRRC4/NGL-2,
miR-182 and AP-2 was involved in glioma development
[43,45,46].
The LRRC4/NGL-2-miR-185/SP1-DNMT1-LRRC4/NGL-2 Loop
MiRNAs regulate the epigenetic modification of genes
through modulating the expression of DNMT (DNA
methyltransferase), maintaining DNA methylation and
mediating histone modifications [54-57]. During tumori-
genesis, miRNAs not only mediate the methylation of
DNAs by regulating DNMT but also can be methylated
in its promoter. Thus, a miRNA-DNMT regulatory loop
might be formed between miRNAs and DNMT [58-60].
The overexpression of LRRC4/NGL-2 could increase
the expression of miR-185, while miR-185 could regulate
global methylation by inhibiting DNA methyltransferase
DNMT1 and increasing the expression of such hyperme-
thylation genes such as LRRC4/NGL-2 in the end. It was
indicated that the LRRC4/NGL-2-miR-185-DNMT1-
LRRC4/NGL-2 loop among LRRC4/NGL-2, miR185 andDNMT1 participated in glioma development. In addition,
DNMT1 was positively regulated by SP1, and it could in-
crease the expression of LRRC4/NGL-2, while LRRC4/
NGL-2 could also inhibit SP1 by negatively regulating the
ERK/MAPK and PI-3 K/AKT signal pathway. Therefore, the
LRRC4/NGL-2-SP1-DNMT1-LRRC4/NGL-2 loop formed
among LRRC4/NGL-2, SP1 and DNMT1 took part in the
glioma formation [44,46]. In addition, CDC42 and RhoA
were the direct targets of miR-185. Furthermore, CDC42
and RhoA were inversely correlated with miR-185 expres-
sion in gliomas. LRRC4/NGL-2 mediated its tumor suppres-
sor by regulating miR-185 targets CDC42 and RhoA.
LRRC4/NGL-2 overexpression inhibited glioma cell growth
and invasion through miR-185-mediated CDC42 and RhoA
direct regulation and VEGFA indirect regulation [44].
Briefly, at the time of LRRC4/NGL-2 regulating miR-
NAs as a tumor suppressor, those miRNAs were found
to regulate the binding of transcription factors to DNA
in their target-mediated signal pathways by directly tar-
geting genes (such as LRRC4/NGL-2) or regulating the
methylation and expression of such hypermethylation
genes such as LRRC4/NGL-2 by directly targeting DNA
methyltransferase and controlling global methylation.
Thus, multiphase loops, which had a core of LRRC4/NGL-2,
were formed (Figure 3) [46]. They were LRRC4/NGL-2-AP-2-
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LRRC4/NGL-2 and LRRC4/NGL-2-SP1-DNMT1-LRRC4/
NGL-2. These loops were involved in glioma development
with multiple positive feedback formations among them.
Conclusions
LRRC4/NGL-2, a member of the LRR superfamily thought
to be involved in tumorigenesis and the development of
the nervous tissues, has the potential to suppress gliomas
cell growth, angiogenesis and invasion through complex
regulation networks. In addition, LRRC4/NGL-2 has the
ability to form multiphase loops with miRNA, transcrip-
tion factors and target genes. These loops are involved in
glioma development with multiple positive feedback for-
mations among them. The results from studies on LRRC4/
NGL-2 suggest that LRRC4/NGL-2 is not only a brain-
specific gene, but it has been identified as a tumor suppres-
sor gene for gliomas. Therefore, the loss of LRRC4/NGL-2
function may be an important event in multiple biological
processes related to gliomas.
There are still many interesting questions that need to
be addressed in future studies. Does the missing LRRC4/
NGL-2 gene affect the development of the central ner-
vous system? Does the lack of LRRC4/NGL-2 expression
result in impaired learning and memory performance?
To answer these questions, the role of LRRC4/NGL-2 in
central nervous development and function should be
verified through in vivo studies employing neuron-
specific knockout mice.
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